Runx2/Cbfa1 is a member of the Runt-related transcription factor family and is an essential regulator of osteoblast/ chondrocyte differentiation. Recently, aberrant expression of Runx2 and its oncogenic functions have been identified in the progression and metastasis of human cancers. In this study, we investigated the expression profile of Runx family genes in normal thyroid tissue, non-neoplastic but abnormal thyroid tissue, various types of thyroid tumors and representative human thyroid carcinoma cell lines. Using reverse transcriptase-PCR and western blotting, we found that Runx2 was consistently upregulated in papillary carcinomas (PCs) and thyroid carcinoma cell lines compared with normal thyroid tissue. With immunohistochemistry, we observed negative or focal immunoreactivity of Runx2 in the nuclei of normal thyroid follicular cells. None of the non-neoplastic thyroid tissues, including Graves' thyroid and adenomatous goiter, had diffuse positivity of Runx2. Expression of Runx2 in benign follicular adenomas varied from negative to diffusely positive. Meanwhile, all malignant thyroid tumors showed some Runx2 immunopositivity. It was diffuse and intense in 83% (19/23) of PCs, 71% (5/7) of follicular carcinomas (FCs) and 40% (4/10) of undifferentiated carcinomas (UCs). In thyroid carcinoma cell lines, the MEK inhibitor U0126 suppressed Runx2, suggesting an association of the MAPK/ERK pathway with Runx2 regulation. Effective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells. We also confirmed that Runx2 silencing suppresses thyroid carcinoma cell invasion in transwell assays. In conclusion, this study provides insight into the potential molecular mechanism of thyroid cancer invasion. Our data suggest that enhanced Runx2 is functionally linked to tumor invasion and metastasis of thyroid carcinoma by regulating EMT-related molecules, matrix metalloproteinases and angiogenic/lymphangiogenic factors.
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1 This wide spectrum of progression has been closely linked with a pattern of cumulative genetic defects and epigenetic gene dysregulation that correlates with tumor differentiation, metastatic potential and aggressiveness. 2 However, the molecular mechanism of invasion and the epithelial-mesenchymal transition (EMT) phenomenon in thyroid carcinoma must still be clarified. The mammalian runt-related transcription factor (Runx) genes, including RUNX1 (AML1/CBFA2), RUNX2 (AML2/ CBFA1) and RUNX3 (AML3/CBFA3), encode transcription factors that are master regulators of proliferation and differentiation during embryonic development. Runx proteins form a heterodimeric complex with a non-DNA-binding partner, that is, a core-binding factor-b (CBFb). All three Runx proteins have a conserved 128-amino acid Runt domain that mediates DNA binding and heterodimerization with the CBFb. Despite their highly homologous Runt domains, Runx family genes show tissue-specific divergent functions. For instance, Runx1 is essential for definitive hematopoiesis including erythroid cells, granulocytes, macrophages and lymphocytes. Runx2 is required for chondroosteoblast lineage differentiation. Runx3 is associated with the regulation of gastric epithelial growth, thymopoiesis and neurogenesis of the dorsal root ganglia. 3 Aberrant regulation of the Runx family has been highlighted recently in tumor pathogenesis. Runx1 is frequently involved in acute myelogenous leukemias and myelodysplastic syndromes through acquired chromosomal rearrangement and point mutations. 4 Overexpression of Runx2 is observed in prostate, pancreas and breast cancers. 5, 6 Functional inactivation of Runx3 by hemizygous deletion, promoter DNA hypermethylation and/or histone modification were found in human solid tumors. 7 Although tumor-suppressive roles have been suggested in Runx1 and Runx3, Runx2 is being recognized as a tumorpromoting factor in several human cancers. Runx2 promotes the metastatic ability of cancer cells by enhancing the secretion of various types of matrix metalloproteinases (MMPs) and VEGF, a key angiogenic factor. [8] [9] [10] Furthermore, upregulation of Runx2 induces EMT-related molecules such as SOX9, Snail2/Slug/SNAI2 and SMAD3 that potentially enhance invasion of cancer cells. 11, 12 In thyroid cancers, overexpression of EMT-related proteins, including Runx2, has been reported; however, little is known about the expression profile of the Runx family and their biological functions in thyroid carcinogenesis. 13 In this study, we hypothesized that the regulation of cancer invasion and the EMT phenomenon in thyroid carcinomas could be attributed to functional aberrations of the Runx family. Here, we evaluate the expression profile of Runx genes in various thyroid tissues and thyroid carcinoma cell lines. Following confirmation of Runx2 upregulation, we explore the cancer-promoting properties of Runx2 in thyroid carcinomas.
MATERIALS AND METHODS Case Selection
We investigated 107 surgical specimens representing a range of thyroid pathologies from routine surgical pathology files at University of Yamanashi Hospital, Yamanashi, Japan, including normal thyroid (21 cases), Graves' disease (11 cases), adenomatous goiter (16 cases), follicular adenoma (19 cases), FC (7 cases), PC (23 cases) and UC (10 cases). All slide specimens were stained with hematoxylin-eosin (HE), and the diagnosis was made on the basis of the World Health Organization classification.
14 Normal thyroid tissues were obtained from patients who underwent subtotal or total thyroidectomy for PC. The snap-frozen tissues were stored at À80 1C before subsequent isolation of their RNA. The institutional ethics board of the University of Yamanashi approved the protocols.
Cell Lines and Cell Culture
Human thyroid carcinoma-derived cell lines, WRO, TPC-1, KTC-1, 8505C, 8305C and TT, have already been described. 15, 16 UA-1 and UA-2 were originally established cell lines derived from human UC. Cells were maintained in RPMI-1640 (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), streptomycin sulfate (100 mg/ml) and penicillin G sodium (100 U/ml). Cells were cultured in a standard humidified incubator at 37 1C in a 5% carbon dioxide atmosphere.
To determine RUNX2 expression, cultured cells were treated with graded concentrations of FBS (0, 1, 5 and 10%) in medium for 24 h after 24 h of serum starvation. For MEK inhibition, U0126 (Calbiochem, San Diego, CA, USA) was added to the medium at a concentration of 4 mM for 1 h, followed by 10% FBS treatment. To prepare the cell pellets, semiconfluent plates were washed, gently scraped and centrifuged into pellets that were coated in 2% bactoagar until solidified, fixed in 10% formalin and embedded in paraffin.
RNA Extraction and Reverse Transcription-PCR
We isolated total RNA from fresh frozen tissues and cultured cells using TRIzol (Invitrogen, Carlsbad, CA, USA) and generated cDNA using the TaqMan reverse transcription (RT) reagent kit (Applied Biosystems, Foster City, CA, USA). Specific PCR primers targeted for RUNX1, RUNX2 and RUNX3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, as an internal control) were designed as listed in Table 1 . We used the HotStarTaq DNA polymerase kit (Qiagen, Tokyo, Japan) for amplification. PCR conditions were as follows: (1) Quantitative Real-Time PCR We performed real-time PCR with MyiQ Single-Color Realtime PCR detection system (Applied Biosystems). Approximately 2.5 ml cDNA was amplified in each 25 ml PCR reaction mix containing 12.5 ml of 2 Â SYBR Green Master Mix (Qiagen), 0.75 ml each of 10 mM forward and reverse primers and 8.5 ml of DEPC-treated water. Amplification was started at 95 1C for 15 min as the first step, followed by 45 cycles of PCR: at 95 1C for 30 s, at 58 1C for 30 s and 72 1C for 60 s, successively. We normalized the amount of the target gene mRNA to that of GAPDH using the threshold cycle method, as described in the manufacturer's protocol. PCR primers used in real-time PCR are listed in Table 1 .
Immunohistocytochemistry
We performed immunohistochemical and immunocytochemical analysis on 3 mm sections of routinely processed formalin-fixed and paraffin-embedded tissues or the cell pellets described above. A detailed protocol has been Runx2 in thyroid carcinoma D-F Niu et al previously described. 17 Briefly, following antigen retrieval (citrate buffer, pH 6.0, autoclave for 10 min), deparaffinized sections were incubated with anti-Runx-1 mouse-monoclonal antibody (clone 2C10; Abnova, Taipei, Taiwan; 1:50), antiRunx2 mouse-monoclonal antibody (clone 3F5; Abnova; 1:50) or anti-Runx-3 purified MaxPab mouse polyclonal antibody (Abnova; 1:200) for 1 h at room temperature. To visualize the reaction, we carried out the labeled polymer method (Envision Detection System; Dako, Glostrup, Denmark) according to the manufacturer's instructions. Positive control was as follows: stomach for Runx1, human placenta for Runx2 and endometrium for Runx3. The immunoreactivity was evaluated as absent, mild, moderate and strong: absent, no immunoreactivity; mild, focal immunoreactivity (1 to 9% positive cells); moderate, intermediate immunoreactivity between mild and strong; strong, diffuse immunoreactivity (450% positive cells).
Using a protocol of immunocytofluorescence as previously described, 18 we used primary antibodies and working dilution rates as follows: anti-Runx2 mouse-monoclonal antibody (Abnova; 1:100), anti-SNAI-2/Slug rabbit polyclonal antibody (LS-B554; LifeSpan Biosciences, Seattle, WA, USA; 1:400), anti-MMP-2 rabbit polyclonal antibody (ab37150; Abcam, Cambridge, UK; 1:250) and anti-VEGF-C rabbit polyclonal antibody (no. 18415; Immuno-Biological Laboratories, Gunma, Japan; 1:20). Fluorescein isothiocyanate (FITC)-conjugated immunoglobulin (Dako) was used as a secondary antibody. For a nuclear counterstain, slides were mounted with mounting medium containing 4 0 ,6-diamino-2-phenylindole (DAPI/H-1200, Vector Laboratories, Burlingame, CA, USA). To visualize the fluorescence, we used an epi-illumination fluorescence light microscope (BX50; Olympus, Tokyo, Japan) and a high sensitivity cooled CCD camera (DP30BW; Olympus).
Protein Isolation and Western Blotting
Cultured cells were lysed in a radioimmunoprecipitation assay (RIPA) lysis buffer with proteinase inhibitors (1 Â phosphate-buffered saline (PBS), 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride (PMSF), 12 mg/ml aprotinin and 1 mM sodium orthovanadate). Equal amounts of protein (30 mg) solubilized in sample buffer were separated on 10% SDS polyacrylamide gels and transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in Tris-buffered saline (TBS) containing 0.05% Tween-20 plus 5% nonfat dried milk for 1 h at room temperature and then probed with primary antibodies at 4 1C overnight. Primary antibodies were used at the specified dilutions: anti-Runx2 (1:1000), anti-Snail2/Slug(1:1000), anti-MMP-2 (1:1000), anti-phospho-ERK (Sigma; 1:1000), anti-total ERK (Sigma; 1:5000) and anti-b-actin (Abcam; 1:5000). Membranes were washed three times for 15 min each in TBS containing 0.05% Tween-20 and incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse/rabbit secondary antibody at 1:2000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. We visualized the targeted proteins using an enhanced chemiluminescence detection system (Amersham, Buckinghamshire, UK).
Small Interfering RNA Transfection
We grew WRO and 8305C cells in RPMI-1640 supplemented with 0.5% FBS in six-well culture plates until 50% confluence. Runx2 short interfering RNA (siRNA) transfection was performed using HiperFect transfection reagent (Qiagen) according to the manufacturer's instructions. The Runx2 target sequence was 5 0 -CAGAAGCTTGACTCTAAA-3 0 , and AllStars negative control siRNA (Qiagen) was used as a control. We confirmed alterations of Runx2 expression with RT-PCR, real-time PCR and immunocytochemistry.
Invasion and Migration Assays
We assessed cell motility in a transwell assay using 24-well plates with uncoated inserts to examine migration or in Matrigel-coated inserts to assess invasiveness (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, the upper and lower culture compartments were separated by polycarbonate filters with a pore size of 8 mm. After trypsinization, 2 Â 10 4 cells were plated in each insert with 500 ml of serum-free medium. The growth medium containing 10% FBS was used as a chemoattractant in the bottom well. After 24 h of incubation, cells on the upper surface were removed by scrubbing with a cotton swab. Cells on the lower surface of the membrane were stained with Diff-Quik stain and quantified by light microscopy. Assays were done in triplicate. Data are presented as mean ± s.d.
Statistics
We set statistical significance at Po0.05, and performed data analyses with SPSS version 13.0 for windows (SPSS, Tokyo, Japan).
RESULTS

Expression Profiles of Runx Genes in Thyroid Tumors
We investigated the expression pattern of the Runx gene family in thyroid carcinomas by RT-PCR. The PC tissues had a consistently higher expression level of RUNX1 and RUNX2 mRNA compared with normal thyroid tissues in 4 of 4 cases (Figure 1a) . On the other hand, 2 of 4 PC cases had a lower expression level of RUNX3 mRNA.
Then, we focused on Runx2 in thyroid tumors. Using immunohistochemistry, we assessed the expression of Runx2 protein in various histological types of thyroid (Figure 1b) . Table 2 summarizes these immunohistochemical results. We saw positive immunostaining of Runx2 in the nuclei of cells. In normal thyroid tissue, follicular cells exhibited negative (absent) or focal positivity (mild) in 71% (15/21) and 29% (6/21) of cases, respectively. In detail, positive follicular cells were cuboidal comprising small follicles. The expression pattern of Runx2 varied from absent to moderate in Graves' thyroid and adenomatous goiter, and we did not see any strong positivity of Runx2 in these non-neoplastic thyroid diseases. Runx2 immunostaining in benign follicular adenomas varied from absent to 11% (2/19) being strong positive. Immunohistochemical intensity of Runx2 in follicular adenomas was rather weak compared with the intensity in thyroid carcinomas. Furthermore, all malignant thyroid tumors were immunopositive for Runx2. It was diffuse and intense (strong) in 83% (19/23) of PCs, 71% (5/7) of FCs and 40% (4/10) of UCs. Representative immunostaining for Runx1 and Runx3 are demonstrated in Figure 1c and d.
Runx Genes in Thyroid Carcinoma Cell Lines
We also examined expression of the Runx family in eight thyroid carcinoma cell lines (Figure 2a) . Using RT-PCR, we detected RUNX1 mRNA in seven cell lines and RUNX2 mRNA in six cell lines. RUNX3 mRNA was detected in one cell line (8505C cells). All cell lines that expressed Runx family genes were follicular cell derived. We did not detect any Runx family genes in the C cell-derived TT cell line. Western blotting confirmed Runx2 protein expression in KTC-1, TPC-1, WRO, UA-2 and 8305C cells (Figure 2b) . Immunocytochemistry demonstrated nuclear localization of Runx2 in WRO, TPC-1 and 8305C cells (Figure 2c ). Neither RUNX2 mRNA nor Runx2 protein was detected in 8505C cells.
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Regulation of Runx2 Expression in Thyroid Carcinoma Cells
Based on enhanced expression of Runx2 in thyroid carcinomas, we investigated the relationship between mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling consequence and Runx2 expression. We stimulated Runx2-positive cells (WRO and TPC-1) with various concentrations of FBS (0, 1, 5 and 10%) and MEK inhibitor (U0126), and then assessed RUNX2 mRNA expression by RT-PCR (Figure 3a ) and real-time PCR (Figure 3b ). We found that RUNX2 mRNA increased with serum stimulation in a concentration-dependent manner, whereas treatment of MEK inhibitor significantly suppressed RUNX2 expression in both cell lines (Po0.05). Immunocytofluorescence confirmed induction of Runx2 expression under serum stimulation in WRO and TPC-1 cells (Figure 3c) . We further validated the results of PCR, 
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immunocytofluorescence and MAPK/ERK inhibition by western blotting (Figure 3d ).
Runx2 Association with EMT-Related Molecules and Angiogenic Factors
To explore the roles of Runx2 in thyroid carcinoma, we performed siRNA-mediated gene silencing against Runx2. We selected WRO and 8305 cells based on their endogenous expression of Runx2. Conventional RT-PCR and real-time PCR confirmed effective knockdown of RUNX2 mRNA in WRO and 8305C (Figure 4a and b) . As shown in Figure 4c , Runx2 protein was positive in the nuclei of control cells, whereas it was negative or weakly positive in the nuclei of RUNX2 siRNA-treated WRO or 8305C cells. Following confirmation of the effective Runx2 knockdown, we next examined the potential targets of Runx2, focusing on EMT-related molecules (SNAI1, SNAI2, SNAI3 and TWIST1), MMPs (MMP1, MMP2 and MMP9) and vasculogenic factors (VEGFA and VEGFC). Through RT-PCR, we found that Runx2 silencing resulted in a decreased mRNA expression of SNAI2 and VEGFC in WRO cells by ( Figure  4a) . The Runx2-silenced 8305C cells also showed downregulation of SNAI2, SNAI3, TWIST1, MMP2, VEGFA and VEGFC. The significant downregulation in these genes was quantitatively validated in both cell lines using real-time PCR (Po0.05; Figure 4b ). Immunocytofluorescence staining showed decreased expression of Snail2/Slug (SNAI2) and VEGFC in Runx2 siRNA/WRO cells compared with control cells (Figure 4c ). We confirmed downexpression of MMP2 in Runx2 siRNA/8305C cells. Runx2 knockdown presented no alteration of SNAI1, MMP1 and MMP9 in either cell line. The results of PCR and immunocytofluorescence were further validated by western blotting (Figure 4d ).
Runx2 Silencing Impedes Invasion of Thyroid Carcinoma Cells
Having determined that Runx2 targets EMT-related molecules and MMP in thyroid cancer cells, we next examined the contribution of Runx2 to cancer cell invasion using transwell assays. In WRO cells that express endogenous Runx2, we found that Runx2 silencing unequivocally suppressed cell invasion compared with the control (P ¼ 0.03), whereas there was no significant effect on cell migration (P ¼ 0.112; Figure 5a and b).
DISCUSSION
Transcription factor Runx2 (RUNX2/CBFA1) is a member of the Runx family, and has an essential role in osteoblastic differentiation and osteogenesis by regulating osteoblastspecific genes such as osteopontin and osteocalcin. 19 Recently, its alternative role has been emphasized in carcinogenesis. 20 In this study, we found there was focal and weak expression of Runx2 in normal thyroid and benign thyroid lesions, and diffuse and intense expression in thyroid carcinomas including PCs, FCs and UCs.
The function of thyroid follicles is heterogeneously synchronized in a normal thyroid under the same supply of thyrotropin in the blood. Our previous studies demonstrated this follicular heterogeneity in normal thyroid with enzyme histochemistry for ecto-5 0 -nucleotidase and with immunohistochemistry for thyroid-specific proteins including TTF-1, Tg, thyroid peroxidase and pendrin. 17, 21 Recently, Endo and Kobayashi 22 reported that Runx2 þ /À heterozygous mice are in a hypothyroid state. In this seminal study, they demonstrated that Runx2 binds to the Tg promoter region and regulates Tg expression in FRTL-5 cells. Our immunohistochemistry revealed focal expression of Runx2 in 29% of normal thyroids. We presume that heterogeneous expression of Runx2 immunoreactivity reflects functional heterogeneity of thyroid follicles. However, the physiological role of Runx2 in follicular cells of normal or non-neoplastic thyroid lesions is still to be elucidated.
We showed that Runx2 is upregulated in various types of follicular cell-derived thyroid carcinomas. This finding suggested to us that enhanced expression of Runx2 has some tumor-promoting properties in thyroid carcinomas. Indeed, a Runx2 role has been emphasized in several human cancers such as prostate cancer and breast cancer. 20 Runx2 expression is higher in prostate cancer and invasive breast cancer compared with corresponding non-neoplastic or non-invasive lesions. [23] [24] [25] Enhanced Runx2 expression in prostate cancer is associated with disease progression including higher Gleason scores. 8 In breast cancers with a high labeling index of Runx2, the clinical outcome of the breast cancer was worse; Runx2 is used as an independent prognostic factor in these patients. 23 An increasing number of studies have suggested oncogenic functions of Runx2 in carcinoma cells. It is reported that Runx2 regulates expression of survivin that inhibits caspase activity, leading to an antiapoptotic effect, and the report demonstrated that signaling by bone morphogenic protein (BMP) enhances Runx2 expression in prostate cancer. 26 Zhang et al 27 reported that Runx2 binds the promoter region of LGAL3 (galectin-3) and regulates galectin-3 levels in the pituitary tumors. The relation of Runx2 and galectin-3 would be challenging issue for future studies in thyroid cancers, as malignant thyroid tumors frequently express higher level of galectin-3 as well as Runx2. 28 It leads us to surmise that galectin-3, which plays oncogenic functions in human cancers and ancillary diagnostic marker of thyroid carcinomas, is also a direct target gene of Runx2.
Runx2 is also associated with invasion and metastasis of prostatic carcinoma cells by regulating MMP9, MMP13, VEGF and osteopontin. 8, 20 In breast carcinoma cells, expression of Runx2 is shown to be important in the positive regulation of angiogenic factors, and Runx2-regulated MMPs are functionally related to the invasion properties of breast cancer cells. 29, 30 Likewise, our current study demonstrated that Runx2 expression is involved with positive regulation of angiogenic factors (VEGFA, VEGFC), MMP2 and EMTrelated molecules (SNAI2, SNAI3, TWIST1) in thyroid carcinoma. Furthermore, we showed that Runx2 silencing repressed the invasion of thyroid carcinoma cells in the transwell cell invasion assay. These data suggest a key role of Runx2 in the molecular mechanism of thyroid cancer invasiveness.
The EMT phenomenon, which is characterized by loss of cell adhesion, repression of E-cadherin expression and increased cell mobility has been implicated in cancer invasiveness and metastasis. Vasko et al 13 demonstrated that EMT-related molecules, including Runx2, were upregulated, particularly in the invasive region of the PC. They also revealed that vimentin, an overexpressed EMT marker in the PC, is required for thyroid cancer cell invasion. In our study, we observed a high frequency and high intensity of Runx2 immunopositivity in various types of invasive thyroid carcinomas. Furthermore, we showed Runx2 to be positively linked with the expression of Twist1 and the Snail family in thyroid carcinoma cells. Twist1 is a helix-loop-helix transcription factor and a promoter of the EMT process mediated by E-cadherin suppression. The Snail family is a group of zinc-finger transcription factors consisting of Snail1/SNAI1, Snail2/Slug/SNAI2 and Snail3/SNAI3. 31 This family of transcription factors also contributes to EMT by E-cadherin downregulation. Recently, Casas et al 32 demonstrated Snail2/ Slug as the direct transcription target of Twist1, and it is required for the Twist1-induced E-cadherin suppression. Although expression of Twist1 and the Snail transcription factors are regulated by an integrated and complex signaling pathway, our current data suggest that Runx2 is one of the regulators of these EMT-inducing factors. Taken together, inhibition of Runx2 would be a potential therapeutic approach against invasion and metastasis of thyroid carcinomas.
In osteoblasts, MAPK/ERK activation enhances the transcriptional activity of Runx2 and promotes osteoblast differentiation, 33, 34 which supports the results of our study. Expression of Runx2 was significantly suppressed by selective MEK inhibition, suggesting that regulation of Runx2 is dependent on the MAPK/ERK pathway in thyroid carcinoma cells. Persistent activation of MAPK/ERK signaling because of genetic alteration, such as RET rearrangements, NTRK rearrangements and activating somatic mutations in RAS and BRAF oncogenes, is a feature of most follicular cell-derived carcinomas including FCs, PCs and UCs. 1 The enhanced expression of Runx2 observed in various types of thyroid carcinomas is probably attributable to intrinsic gene abnormalities resulting in aberrant activation of MAPK/ERK signaling. However, we should take notice that partial loss of serum effect against Runx2 by MEK inhibition also suggests the contribution of alternative pathways other than MAPK/ ERK signaling.
In this study, RUNX1 mRNA is upregulated in PCs compared with normal thyroid tissues along with the expression of RUNX2. In addition, the majority of follicular cell-derived thyroid carcinoma cell lines expressed RUNX1 and RUNX2 mRNA, whereas two of four PC cases had a lower expression of RUNX3 mRNA, and RUNX3 mRNA was detected in only one cell line. These divergent expression patterns of the Runx family suggest that Runx1 and Runx3 also might play a role in the development of thyroid carcinoma. However, further studies regarding Runx1 and Runx3 are needed to clarify their biological roles in the progression of thyroid carcinomas.
In conclusion, this study provides insight into a potential molecular mechanism of thyroid cancer invasion. Our data suggest that enhanced Runx2 is linked to tumor invasion and metastasis of thyroid carcinoma by regulating EMT-related molecules, MMP and angiogenic/lymphangiogenic factors. 
